> one sets the dose low enough to to only edit the genes of, say, half the targeted cells
Using the single-cell sequencing we’ve learned that disease is sometimes driven by a very small sub-population of cells(e.g. cancer treatment resistance). There’s no way of knowing how the organism will respond to a perturbation even in 1% of the cells.
If I'm interpreting the article correctly, though, it sounds like in their trials they think they may have edited nearly all the targeted cells.